Lindbrook Capital’s Checkpoint Therapeutics CKPT Stock Holding History

Lindbrook Capital’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$162K	Sell	40,000 -10,000	-20%	-$33.3K	0.01%	481
2024 Q4	$160K	Hold	50,000	–	–	0.01%	431
2024 Q3	$112K	Buy	50,000 +5,000	+11%	+$11.5K	0.01%	537
2024 Q2	$96.8K	Buy	45,000 +15,000	+50%	+$26.7K	0.01%	552
2024 Q1	$61.5K	Buy	+30,000	New	+$59.8K	0.01%	700
2022 Q4	–	Sell	-300	Closed	-$2.16K	–	2856
2022 Q3	$3K	Hold	300	–	–	﹤0.01%	1853
2022 Q2	$3K	Hold	300	–	–	﹤0.01%	1760
2022 Q1	$5K	Buy	+300	New	+$6.44K	﹤0.01%	1578

Other funds holding CKPT

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

GLF

Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Lindbrook Capital's CKPT Position: Q1 2025 in Review

Lindbrook Capital reduced its Checkpoint Therapeutics (CKPT) stake by 20% in Q1 2025, selling an estimated $33.3K and leaving 40,000 shares worth $162K. The position accounts for 0.01% of the portfolio, ranked #481.

Lindbrook Capital first reported a position in CKPT in Q1 2022 and has held it in 8 quarters since. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

Lindbrook Capital held 40,000 shares of Checkpoint Therapeutics worth $162K as of Q1 2025.
Lindbrook Capital sold 10,000 Checkpoint Therapeutics shares in Q1 2025, an estimated $33.3K.
Checkpoint Therapeutics made up 0.01% of Lindbrook Capital's portfolio in Q1 2025, its #481 holding.
Lindbrook Capital first reported a position in Checkpoint Therapeutics in Q1 2022 and has held it in 8 quarters since.
84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.